Abreva enters new markets
This article was originally published in The Tan Sheet
Cold sore remedy approved for OTC sale in Canada, could be available by year end under exclusive licensing agreement with GlaxoSmithKline, Avanir Pharmaceuticals says May 28. Deal with GSK, which was announced in March 2000 and also gave GSK U.S. marketing rights to Abreva, provides Avanir with royalties based on wholesale product revenue. Before GSK launches the docosanol 10% cream in Canada, firm must attain provincial approval from the national drug scheduling recommendation committee; GSK is scheduling a presentation before committee for September. Avanir also announces product approvals in Korea, Israel...
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.